Comparison
Buserelin vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
57982-77-1
396091-73-9
Molecular weight
1239.42 g/mol
1047.21 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
1
of which in humans
0
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Buserelin and Pasireotid?
- Buserelin is classified as "Research other", while Pasireotid is classified as "Research other". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or Pasireotid?
- The highest available evidence level is "Human RCT" for Buserelin and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and Pasireotid in Germany and the United States?
- Germany: Buserelin — Prescription, Pasireotid — Prescription. United States: Buserelin — Unapproved, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.